First clinical multicenter experience of the new NeVa NET 5.5 thrombectomy device.

Background: Mechanical thrombectomy for the treatment of acute ischemic stroke has undergone relevant technical improvements over recent years. However, distal emboli and incomplete reperfusion after mechanical thrombectomy are still shortcomings in the care of patients with endovascular acute ischemic stroke. The NeVa NET 5.5 thrombectomy device (Vesalio, Nashville, Tennessee, USA) is the first stent retriever featuring an integrated clot micro-filtration system, aiming to enhance first pass efficacy and reduce distal embolization. This study evaluates the safety and efficacy of the NeVa NET 5.5 thrombectomy device.

Methods: Patients with acute anterior circulation occlusions and vessel diameters >2 mm treated with the NeVa NET 5.5 stent retriever as a first-line approach were retrospectively included in this study. Data were collected from three European comprehensive stroke centers between October 2022 and April 2024. Patient data, occlusion details, clinical outcomes, and procedure-related parameters were analyzed.

Results: A total of 51 patients were included. The most common occlusion locations were the internal carotid artery terminus and intradural internal carotid artery (70.6%). The mean±SD clot length was 25.1±13.3 mm (range 4-50 mm). First pass reperfusion (eTICI 2b-3) was achieved in 78.5%, with a final reperfusion rate of eTICI 2b-3 in 98.1%. Distal embolization in new territories occurred in 3.9%. No device-related adverse events were reported, and procedure-related adverse events occurred in 7.6% of the overall included cases.

Conclusion: The NeVa NET 5.5 stent retriever has a high first pass reperfusion rate in large vessel occlusions of the anterior circulation, with a good safety profile and low rate of distal embolization.